Literature DB >> 35378710

KRASG12R-Independent Macropinocytosis in Pancreatic Cancer.

G Aaron Hobbs1,2, Channing J Der3,4,5.   

Abstract

Macropinocytosis is a critical route of nutrient acquisition in pancreatic cancer cells. Constitutive macropinocytosis is promoted by mutant KRAS, which activates the PI3Kα lipid kinase and RAC1, to drive membrane ruffling, macropinosome uptake and processing. However, our recent study on the KRASG12R mutant indicated the presence of a KRAS-independent mode of macropinocytosis in pancreatic cancer cell lines, thereby increasing the complexity of this process. We found that KRASG12R-mutant cell lines promote macropinocytosis independent of KRAS activity using PI3Kγ and RAC1, highlighting the convergence of regulation on RAC signaling. While macropinocytosis has been proposed to be a therapeutic target for the treatment of pancreatic cancer, our studies have underscored how little we understand about the activation and regulation of this metabolic process. Therefore, this review seeks to highlight the differences in macropinocytosis regulation in the two cellular subtypes while also highlighting the features that make the KRASG12R mutant atypical.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  KRAS; Macropinocytosis; Metabolism; Mutant-specific signaling; PI3K; Pancreatic cancer

Mesh:

Substances:

Year:  2022        PMID: 35378710     DOI: 10.1007/978-3-030-94004-1_11

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN: 0306-0225


  57 in total

Review 1.  Uses and abuses of macropinocytosis.

Authors:  Gareth Bloomfield; Robert R Kay
Journal:  J Cell Sci       Date:  2016-06-27       Impact factor: 5.285

2.  Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins.

Authors:  D Bar-Sagi; J R Feramisco
Journal:  Science       Date:  1986-09-05       Impact factor: 47.728

3.  Determining the macropinocytic index of cells through a quantitative image-based assay.

Authors:  Cosimo Commisso; Rory J Flinn; Dafna Bar-Sagi
Journal:  Nat Protoc       Date:  2014-01-02       Impact factor: 13.491

4.  RAS Interaction with PI3K: More Than Just Another Effector Pathway.

Authors:  Esther Castellano; Julian Downward
Journal:  Genes Cancer       Date:  2011-03

5.  Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.

Authors:  Shih-Hsun Chen; Youyan Zhang; Robert D Van Horn; Tinggui Yin; Sean Buchanan; Vipin Yadav; Igor Mochalkin; Swee Seong Wong; Yong Gang Yue; Lysiane Huber; Ilaria Conti; James R Henry; James J Starling; Gregory D Plowman; Sheng-Bin Peng
Journal:  Cancer Discov       Date:  2016-01-05       Impact factor: 39.397

6.  Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α.

Authors:  Romain Baer; Célia Cintas; Marlène Dufresne; Stéphanie Cassant-Sourdy; Nina Schönhuber; Laetitia Planque; Hubert Lulka; Bettina Couderc; Corinne Bousquet; Barbara Garmy-Susini; Bart Vanhaesebroeck; Stéphane Pyronnet; Dieter Saur; Julie Guillermet-Guibert
Journal:  Genes Dev       Date:  2014-12-01       Impact factor: 11.361

7.  Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

Authors:  Aditya Bardia; Mrinal Gounder; Jordi Rodon; Filip Janku; Martijn P Lolkema; Joe J Stephenson; Philippe L Bedard; Martin Schuler; Cristiana Sessa; Patricia LoRusso; Michael Thomas; Heiko Maacke; Helen Evans; Yongjian Sun; Daniel S W Tan
Journal:  Oncologist       Date:  2019-08-08

Review 8.  PI3K isoforms in cell signalling and vesicle trafficking.

Authors:  Benoit Bilanges; York Posor; Bart Vanhaesebroeck
Journal:  Nat Rev Mol Cell Biol       Date:  2019-09       Impact factor: 94.444

9.  Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells.

Authors:  Cosimo Commisso; Shawn M Davidson; Rengin G Soydaner-Azeloglu; Seth J Parker; Jurre J Kamphorst; Sean Hackett; Elda Grabocka; Michel Nofal; Jeffrey A Drebin; Craig B Thompson; Joshua D Rabinowitz; Christian M Metallo; Matthew G Vander Heiden; Dafna Bar-Sagi
Journal:  Nature       Date:  2013-05-12       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.